Incidence and Outcomes of Brain Metastases in Unresectable Stage III Patients with NSCLC Treated with Durvalumab after Chemoradiation

被引：0
|
作者：
Patel, S. [1 ]
Zhao, S. [2 ]
Wei, L. [2 ]
Li, M. [3 ]
Bertino, E. [3 ]
Presley, C. [3 ]
Welliver, M. [3 ]
Haglund, K. [3 ]
Palmer, J. [3 ]
Arnett, A. [3 ]
Beyer, S. [3 ]
Mende, E. [3 ]
Elder, J. [3 ]
Hardesty, D. [3 ]
Shields, P. [4 ]
Carbone, D. [4 ]
Otterson, G. [4 ]
Williams, T. [3 ]
Owen, D. [4 ]
机构：
[1] Ohio State Univ, Ctr Comprehens Canc, Hematol Med Oncol, Columbus, OH 43210 USA
[2] Ohio State Univ, Ctr Comprehens Canc, Biostat, Columbus, OH 43210 USA
[3] Ohio State Univ, Ctr Comprehens Canc, Columbus, OH 43210 USA
[4] Ohio State Univ, Ctr Comprehens Canc, Med Oncol, Columbus, OH 43210 USA
来源：
JOURNAL OF THORACIC ONCOLOGY | 2021年 / 16卷 / 03期
关键词：
Stage III NSCLC; Brain Metastasis; Durvalumab;
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
P21.02
引用
收藏
页码：S363 / S364
页数：2
相关论文
共 50 条
  • [41] SPOTLIGHT real-world study: Outcomes with or without consolidation durvalumab (D) after chemoradiotherapy (CRT) in patients with unresectable stage III NSCLC
    Whitaker, R. M.
    Cai, L.
    Wang, A.
    Qiao, Y.
    Chander, P.
    Mooradian, M.
    JOURNAL OF THORACIC ONCOLOGY, 2023, 18 (04) : S111 - S111
  • [42] Osimertinib Maintenance After Definitive Chemoradiation in Patients with Unresectable EGFRm-Positive Stage III NSCLC (LAURA)
    Shun, L.
    Nash, T.
    Saggese, M.
    Mann, H.
    Ramalingam, S.
    JOURNAL OF THORACIC ONCOLOGY, 2018, 13 (10) : S497 - S497
  • [43] Impact of prior chemoradiotherapy-related variables on outcomes with durvalumab in unresectable Stage III NSCLC (PACIFIC)
    Faivre-Finn, Corinne
    Spigel, David R.
    Senan, Suresh
    Langer, Corey
    Perez, Bradford A.
    Ozguroglu, Mustafa
    Daniel, Davey
    Villegas, Augusto
    Vicente, David
    Hui, Rina
    Murakami, Shuji
    Paz-Ares, Luis
    Broadhurst, Helen
    Wadsworth, Catherine
    Dennis, Phillip A.
    Antonia, Scott J.
    LUNG CANCER, 2021, 151 : 30 - 38
  • [44] Patient-Reported Outcomes with Durvalumab after Chemoradiation in Locally Advanced, Unresectable NSCLC: Data from PACIFIC
    Hui, R.
    Ozguroglu, M.
    Daniel, D.
    Baz, D.
    Murakami, S.
    Yokoi, T.
    Chiappori, A.
    Lee, K. H.
    De Wit, M.
    Cho, B. Chul
    Gray, J.
    Ryden, A.
    Viviers, L.
    Poole, L.
    Dennis, P.
    Antonia, S.
    JOURNAL OF THORACIC ONCOLOGY, 2017, 12 (11) : S1604 - S1604
  • [45] 5-year survival outcomes with durvalumab after chemoradiotherapy in unresectable Stage III NSCLC - an update from the PACIFIC trial
    de Wit, M.
    Spigel, D. R.
    Faivre-Finn, C.
    Gray, J. E.
    Vicente, D.
    Planchard, D.
    Paz-Ares, L.
    Vansteenkiste, J. F.
    Garassino, M. C.
    Hui, R.
    Quantin, X.
    Rimner, A.
    Wu, Y. -L
    Oezgueroglu, M.
    Lee, K. H.
    Kato, T.
    Macpherson, E.
    Newton, M.
    Thiyagarajah, P.
    Antonia, S. J.
    Reck, M.
    ONCOLOGY RESEARCH AND TREATMENT, 2021, 44 : 109 - 110
  • [46] PACIFIC-6: A Phase II Study of Durvalumab after sequential Chemoradiotherapy in Patients with unresectable Stage III NSCLC
    Wuerschmidt, F.
    Garassino, M.
    Faivre-Finn, C.
    Mazieres, J.
    Emeribe, U.
    Franks, A.
    Trunova, N.
    Reck, M.
    STRAHLENTHERAPIE UND ONKOLOGIE, 2020, 196 (SUPPL 1) : S88 - S88
  • [47] Durvalumab Consolidation After Chemoradiotherapy in Elderly Patients With Unresectable Stage III NSCLC: A Real-World Multicenter Study
    Park, Ji Eun
    Hong, Kyung Soo
    Choi, Sun Ha
    Lee, Shin Yup
    Shin, Kyeong-Cheol
    Jang, Jong Geol
    Kwon, Yong Shik
    Park, Sun Hyo
    Choi, Keum-Ju
    Jung, Chi Young
    Eom, Jung Seop
    Kim, Saerom
    Seol, Hee Yun
    Kim, Jehun
    Kim, Insu
    Park, Jin Han
    Kim, Tae Hoon
    Ahn, June Hong
    CLINICAL LUNG CANCER, 2024, 25 (04) : 354 - 364
  • [48] Dynamic Blood Count Changes in Patients with unresectable Stage III NSCLC on Durvalumab Maintenance Therapy after completed Radiochemotherapy
    Guggenberger, J.
    Kenndoff, S.
    Taugner, J.
    Kasmann, L.
    Florsch, B.
    Tufman, A.
    Reinmuth, N.
    Belka, C.
    Eze, C.
    Manapov, F.
    STRAHLENTHERAPIE UND ONKOLOGIE, 2022, 198 (SUPPL 1) : S107 - S108
  • [49] Identification of predictive factors for early relapse in patients with unresectable stage. NSCLC receiving consolidation durvalumab after concurrent chemoradiation therapy
    Nam, Jung Hyun
    Yeo, Chang Dong
    Park, Chan Kwon
    Kim, Sung Kyoung
    Kim, Ju Sang
    Kim, Yong Hyun
    Kim, Jin Woo
    Kim, Seung Joon
    Lee, Sang Haak
    Kang, Hye Seon
    EUROPEAN RESPIRATORY JOURNAL, 2023, 62
  • [50] Incidence of central nervous system metastases (mCNS) and overall survival (OS) in patients with stage III non-small cell lung cancer (NSCLC) treated with definitive chemoradiation followed by durvalumab (Durva)
    Sharp, John
    Zhao, Songzhu
    Patel, Sandip
    Wei, Lai
    Li, Mingjia
    Brownstein, Jeremy
    Welliver, Meng Xu
    Haglund, Karl
    Palmer, Joshua David
    Beyer, Sasha
    Raval, Raju R.
    Shields, Peter G.
    He, Kai
    Kaufman, Jacob
    Memmott, Regan Michelle
    Alahmadi, Asrar
    Carbone, David Paul
    Otterson, Gregory Alan
    Presley, Carolyn J.
    Owen, Dwight Hall
    JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 (16)
12345